VONV vs XBI
Vanguard Russell 1000 Value ETF vs SPDR S&P Biotech ETF
- • VONV has the lower expense ratio at 0.06% vs 0.35% for XBI.
- • VONV pays a higher dividend yield (1.68%).
Side-by-side metrics
| Metric | VONV | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.06% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.68% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $20.39B | $8.30B |
YTD return | 11.95% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.85 | 1.09 |
P/E ratio | 22.84 | — |
Last price | $101.77 | $133.66 |
Inception | — | — |
Issuer | Vanguard | State Street |
VONV top holdings
| BRK-B | Berkshire Hathaway Inc Class B | 2.89% |
| JPM | JPMorgan Chase & Co | 2.45% |
| XOM | Exxon Mobil Corp | 2.35% |
| GOOGL | Alphabet Inc Class A | 1.93% |
| JNJ | Johnson & Johnson | 1.93% |
| AMZN | Amazon.com Inc | 1.80% |
| WMT | Walmart Inc | 1.59% |
| GOOG | Alphabet Inc Class C | 1.59% |
| CVX | Chevron Corp | 1.27% |
| MU | Micron Technology Inc | 1.24% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About VONV
VONV (Vanguard Russell 1000 Value ETF) is Vanguard's large-cap value ETF. Managed by Vanguard, the fund carries $20.4B in assets under management, an expense ratio of 0.06%, a dividend yield of 1.68%. Its largest holding is Berkshire Hathaway Inc Class B (BRK-B), which represents 2.9% of the portfolio. Real Estate is the fund's largest sector exposure at 4.1%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.